# US 2017/0281781 A1 · Injectable tissue adhesive hydrogel including gamma-cyclodextrin and biomedical use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281781 A1
- Document ID: US20170281781A1
- Status: Published application
- Kind: A1
- Application number: 15/475,948
- Filed: 2017-03-31
- Published: 2017-10-05
- Earliest claimed: 2016-04-01
- Assignees: Ajou University Industry-Academic Cooperation Foun Dation; Incheon University Industry Academic Cooperation F Oundation
- Applicants: Ajou University Industry-Academic Cooperation Foundation; Incheon University Industry Academic Cooperation Foundation
- Inventors: Ki Dong PARK; Kyung Min PARK; Yun Ki LEE; Thi Thai Thanh HOANG; Thi Phuong LE
- Web page: https://patentgrep.com/patent/US20170281781A1

## CPC

- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61L 26/0066: {Medicaments; Biocides}
- A61L 26/008: {Hydrogels or hydrocolloids}
- A61L 2400/06: Flowable or injectable implant compositions
- A61L 2430/34: for soft tissue reconstruction
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Provided are an injectable tissue adhesive hydrogel including gamma-cyclodextrin (γ-CD). When such an injectable tissue adhesive hydrogel including the γ-CD is used as a skin glue, based on a fact that the γ-CD has a bigger hydrophobic cavity than that of α- and β-CDs, the injectable tissue adhesive hydrogel including the γ-CD has stronger interactions than host-guest interactions. In addition, hydrogen bonding in the injectable tissue adhesive hydrogel including the γ-CD can improve both cohesiveness and adhesiveness of gelatin. The injectable tissue adhesive hydrogel including the γ-CD having excellent cell viability is used for adhesion of a skin incision, to thereby effectively promote tissue regeneration.

## Claims

### Claim 1

An injectable tissue adhesive hydrogel comprising gamma-cyclodextrin (γ-CD), wherein the injectable tissue adhesive hydrogel is cross-linked in situ by adding horseradish peroxidase and hydrogen peroxide to a mixture comprising at least one γ-CD, which is substituted or unsubstituted with a thiol group, and at least one homogeneous or heterogeneous polymer with a main chain in which phenol or a derivative thereof and at least one functional group selected from an amino group and a carboxyl group are contained.

### Claim 2 (depends on 1)

The injectable tissue adhesive hydrogel of claim 1, wherein the hydrogel is cross-linked in situ by phenol-phenol bonding between phenols or derivatives thereof contained in a side branch of the main chain.

### Claim 3 (depends on 1)

The injectable tissue adhesive hydrogel of claim 1, wherein the hydrogel is cross-linked in situ by hydrogen bonding between a hydroxyl group of the γ-CD and the at least one functional group selected from the amino group and the carboxyl group contained in the main chain of the at least one homogeneous or heterogeneous polymer.

### Claim 4 (depends on 1)

The injectable tissue adhesive hydrogel of claim 1, wherein the hydrogel is bonded by host-guest interaction between the at least one homogeneous or heterogeneous polymer and the γ-CD.

### Claim 5 (depends on 1)

The injectable tissue adhesive hydrogel of claim 1, wherein the main chain of the at least one homogeneous or heterogeneous polymer comprises at least one selected from the group consisting of gelatin, chitosan, heparin, cellulose, dextran, dextran sulfate, chondroitin sulfate, keratin sulfate, dermatan sulfate, alginate, collagen, albumin, fibronectin, laminin, elastin, vitronectin, hyaluronic acid, fibrinogen, and a multi-arm polymer.

### Claim 6 (depends on 5)

The injectable tissue adhesive hydrogel of claim 5, wherein, the multi-arm polymer comprises at least one selected from the group consisting of at least one multi-arm polyethylene glycol (PED), such as 3-arm-PEG, 4-arm-PEG, 6-arm-PEG, or 8-arm-PEG; and 4-arm-PPO-PEO (Tetronic® series).

### Claim 7 (depends on 1)

The injectable tissue adhesive hydrogel of claim 1, wherein a physiochemical property of the hydrogel, such as gelation time, degradation time, mechanical strength, and water content, is adjusted by controlling a concentration of the horseradish peroxidase and the hydrogen peroxide.

### Claim 8 (depends on 1)

The injectable tissue adhesive hydrogel of claim 1, wherein the hydrogel is cross-linked in situ with the aid of a dual syringe kit.

### Claim 9 (depends on 8)

The injectable tissue adhesive hydrogel of claim 8, wherein the dual syringe kit is mounted with a spraying nozzle through which the hydrogel is sprayed.

### Claim 10 (depends on 8)

The injectable tissue adhesive hydrogel of claim 8, wherein the hydrogel is formed into a sheet or a disc using the dual syringe kit in combination with a Teflon mold

### Claim 11 (depends on 1)

A substance for tissue adhesion and hemostasis, comprising the injectable tissue adhesive hydrogel of claim 1.

### Claim 12 (depends on 11)

The substance of claim 11, wherein the substance for hemostasis is applicable to a medical case selected from the group consisting of cerebral nervous surgery including vascular surgery, orthopedic surgery including bone bonding, hemostasis in patient with a laceration, closure of the femoral artery, closure after incision of an eye affected with a cataract, healing of cartilage and articular cartilage, dermal adhesion, hemostasis at incised portions in organs/secretory glands, anastomosis of gastrointestinal organs, and healing of ligaments and tendons.

### Claim 13 (depends on 1)

An implant substance for tissue regeneration and augmentation, comprising the injectable tissue adhesive hydrogel of claim 1.

### Claim 14 (depends on 13)

The implant substance of claim 13, wherein the implant substance is applicable to one selected from the group consisting of cartilage regeneration, bone regeneration, periodontal regeneration, skin regeneration, cardiac tissue regeneration, artificial intraocular lens, spinal cord regeneration, cranial regeneration, vocal regeneration and augmentation, adhesiveness barrier, urinary incontinence treatment, wrinkles removal augmentation, wound dressing, tissue augmentation, and intervertebral disc treatment.

### Claim 15 (depends on 1)

A carrier for delivering a biologically active substance or drug, comprising the injectable tissue adhesive hydrogel of claim 1.

### Claim 16 (depends on 15)

The carrier of claim 15, wherein the biologically active substance or drug is selected from the group consisting of a peptide or protein drug, an antibacterial agent, an anti-cancer agent, and an anti-inflammatory agent, and a combination thereof.

### Claim 17 (depends on 16)

The carrier of claim 16, wherein the peptide or protein drug comprises one selected from the group consisting of fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), bone morphogenetic protein (BMP), human growth hormone (hGH), porcine growth hormone (pGH), granulocyte-colony stimulating factor (G-CSF), erythropoietin (EPO), macrophage colony-stimulating factor (M-CSF), tumor necrosis factor (TNF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), interferon-α,β,γ, interleukin-2 (IL-2), calcitonin, nerve growth factor (NGF), growth hormone releasing hormone, angiotensin, luteinizing hormone releasing hormone (LHRH), luteinizing hormone releasing hormone agonist (LHRH agonist), insulin, thyrotropin-releasing hormone (TRH), angiostatin, endostatin, somatostatin, glucagon, endorphine, bacitracin, mergain, colistin, monoclonal antibodies, vaccines, and a combination thereof.

### Claim 18 (depends on 16)

The carrier of claim 16, wherein the antibacterial agent comprises one selected from the group consisting of minocycline, tetracycline, ofloxacin, fosfomycin, mergain, profloxacin, ampicillin, penicillin, doxycycline, thienamycin, cephalosporin, nocardicin, gentamicin, neomycin, kanamycin, paromomycin, micronomicin, amikacin, tobramycin, dibekacin, cefotaxime, cefaclor, erythromycine, ciprofloxacin, levofloxacin, enoxacin, vancomycin, imipenem, fusidic acid and a combination thereof.

### Claim 19 (depends on 16)

The carrier of claim 16, wherein the anti-cancer agent comprises one selected from the group consisting of paclitaxel, taxotere, adriamycin, endostatin, angiostatin, mitomycin, bleomycin, cisplatin, carboplatin, doxorubicin, daunorubicin, idarubicin, 5-fluorouracil, methotrexate, actinomycin-D and a combination thereof.

### Claim 20 (depends on 16)

The carrier of claim 16, wherein the anti-inflammatory agent comprises one selected from the group consisting of acetaminophen, aspirin, ibuprofen, diclofenac, indometacin, piroxicam, fenoprofen, flubiprofen, ketoprofen, naproxen, suprofen, loxoprofen, cinnoxicam, tenoxicam, and a combination thereof.
